Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: Approved therapies and emerging candidates

Expert Review of Clinical Immunology

Volumn 11, Issue 1, 2014, Pages 93-108

  Dubey, Divyanshu ^a   Kieseier, Bernd C ^b   Hartung, Hans Peter ^c   Hemmer, Bernhard ^d   Miller Little, William A ^a   Stuve, Olaf ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

monoclonal antibodies; MS; multiple sclerosis; pharmacology; therapies

Indexed keywords

ALEMTUZUMAB; DACLIZUMAB; ECULIZUMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; RITUXIMAB; TOCILIZUMAB; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ACUTE PYELONEPHRITIS; AUTOIMMUNE DISEASE; BREAST CANCER; BRONCHOSPASM; COUGHING; DEPRESSION; DIARRHEA; DRUG APPROVAL; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ENTEROCOLITIS; EPIDEMIC MENINGITIS; ERYTHEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; GOODPASTURE SYNDROME; HEADACHE; HERPES SIMPLEX; HUMAN; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTHERAPY; INFECTION; INFUSION RELATED REACTION; JOINT SWELLING; LEUKOCYTOSIS; LEUKOPENIA; LUNG EDEMA; METASTATIC MELANOMA; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NAUSEA; NONHUMAN; NOSE OBSTRUCTION; ORAL MUCOSITIS; PHARYNGEAL EDEMA; PHARYNX DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RELAPSE; REVIEW; SIDE EFFECT; SINUSITIS; TACHYCARDIA; THORAX PAIN; THYROID PAPILLARY CARCINOMA; TRANSIENT ISCHEMIC ATTACK; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERINE CERVIX CANCER; VOMITING; ANIMAL; NEUROMYELITIS OPTICA; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; HUMANS; MULTIPLE SCLEROSIS; NATALIZUMAB; NEUROMYELITIS OPTICA;

EID: 84919794431     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.992881     Document Type: Review

References (104)

1. Sorensen PS. New management algorithms in multiple sclerosis. Curr Opin Neurol 2014;27(3):246-59
2. Buss NA, Henderson SJ, McFarlane M, et al. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 2012;12(5):615-22
3. Nissim A, Chernajovsky Y. Historical development of monoclonal antibody therapeutics. Handb Exp Pharmacol 2008;181:3-18
4. Marziniak M, Meuth S. Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis. Adv Ther 2014;31(9):915-31
5. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84(5):548-58
6. Meeker TC, Lowder J, Maloney DG, et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985;65(6):1349-63
7. Shawler DL, Bartholomew RM, Smith LM, Dillman RO. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985;135(2):1530-5.
8. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 1984;312(5995): 643-6
9. Jones PT, Dear PH, Foote J, et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986;321(6069): 522-5
10. Zhang W, Feng J, Li Y, et al. Humanization of an anti-human TNF-alpha antibody by variable region resurfacing with the aid of molecular modeling. Mol Immunol 2005;42(12):1445-51
11. Nissim A, Hoogenboom HR, Tomlinson IM, et al. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J 1994; 13(3):692-8
12. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997; 15(6):553-7
13. Hanes J, Pluckthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 1997;94(10):4937-42
14. Marks JD, Bradbury A. Selection of human antibodies from phage display libraries. Methods Mol Biol 2004;248:161-76
15. Neri D, Carnemolla B, Nissim A, et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 1997;15(12):1271-5
16. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001;276(9):6591-604
17. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006;103(11):4005-10
18. Maas RA, Dullens HF, Den OW. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother 1993;36(3): 141-8
19. Engelhardt B, Kappos L. Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis 2008;5(1):16-22
20. Freedman MS. Present and emerging therapies for multiple sclerosis. Continuum (Minneap. Minn) 2013; 19(4 Multiple Sclerosis);968-91
21. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(9): 899-910
22. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354(9):911-23
23. Rommer PS, Dudesek A, Stuve O, Zettl UK. Monoclonal antibodies in treatment of multiple sclerosis. Clin Exp Immunol 2014;175(3):373-84
24. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366(20):1870-80
25. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, et al. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol 2012;71(7): 604-17
26. Rommer PS, Zettl UK, Kieseier B, et al. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol 2014; 175(3):397-407
27. Cutter GR, Stuve O. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? Mult Scler 2014;20(10):1304-5.
28. Castro-Borrero W, Graves D, Frohman TC, et al. Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord 2012;5(4):205-20
29. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011;76(22):1858-65
30. Capobianco M, di Sapio A, Malentacchi M, et al. No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation. Eur J Neurol 2014. [Epub ahead of print]
31. Rinaldi F, Seppi D, Calabrese M, et al. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler 2012;18(11): 1640-3
32. Daelman L, Maitrot A, Maarouf A, et al. Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler 2012;18(11):1647-9.
33. Cohen M, Maillart E, Tourbah A, et al. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol 2014;71(4):436-41
34. O Fernandez. Alemtuzumab in the treatment of multiple sclerosis. J Inflamm Res 2014;7:19-27
35. Menge T, Stuve O, Kieseier BC, Hartung HP. Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology 2014;83(1):87-97
36. Williams T, Coles A, Azzopardi L. The outlook for alemtuzumab in multiple sclerosis. BioDrugs 2013;27(3):181-9
37. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380(9856):1819-28
38. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380(9856): 1829-39
39. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46(3):296-304
40. Keene DL, Legare C, Taylor E, et al. Monoclonal antibodies and progressive multifocal leukoencephalopathy. Can J Neurol Sci 2011;38(4):565-71
41. Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011;77(6): 573-9
42. Bielekova B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009;66(4): 483-9
43. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006;103(15):5941-6.
44. Sheridan JP, Zhang Y, Riester K, et al. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. Mult Scler 2011; 17(12):1441-8
45. Chanvillard C, Jacolik RF, Infante-Duarte C, Nayak RC. The role of natural killer cells in multiple sclerosis and their therapeutic implications. Front Immunol 2013;4:63
46. Saghafi H, Rahbar K, Nobakht HA, et al. Efficacy of anti-interleukin-2 receptor antibody (daclizumab) in reducing the incidence of acute rejection after renal transplantation. Nephrourol Mon 2012; 4(2):475-7
47. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010;9(4): 381-90
48. Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013; 381(9884):2167-75
49. Grillo-Lopez AJ. Rituximab: an insider's historical perspective. Semin Oncol 2000; 27(6 Suppl 12):9-16
50. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83(2):435-45
51. Gashi AA, Rexhepi S, Berisha I, et al. Treatment of rheumatoid arthritis with biologic DMARDS (Rituximab and Etanercept). Med Arch 2014;68(1):51-3
52. Grillo-Lopez AJ, White CA, Dallaire BK, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 2000; 1(1):1-9
53. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J 2014;12:13
54. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358(7):676-88.
55. Naismith RT, Piccio L, Lyons JA, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010;74(23):1860-7
56. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009;66(4): 460-71
57. Rommer PS, Patejdl R, Winkelmann A, et al. Rituximab for secondary progressive multiple sclerosis: a case series. Drugs CNS 2011;25(7):607-13
58. Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011;13(3):R75
59. Palazzo E, Yahia SA. Progressive multifocal leukoencephalopathy in autoimmune diseases. Joint Bone Spine 2012;79(4):351-5
60. Kausar F, Mustafa K, Sweis G, et al. Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther 2009;9(7):889-95
61. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378(9805):1779-87
62. Zhang B. Ofatumumab. MAbs 2009;1(4): 326-31
63. Sorensen PS. New management algorithms in multiple sclerosis. Curr Opin Neurol 2014;27(3):246-59
64. Reagan JL, Castillo JJ. Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia. Future Oncol 2014; 10(7):1147-55
65. Kurrasch R, Brown JC, Chu M, et al. Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. J Rheumatol 2013; 40(7):1089-96
66. Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology 2014;82(7): 573-81
67. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011;108(9): 3701-6
68. Mitsdoerffer M, Kuchroo V, Korn T. Immunology of neuromyelitis optica: a T cell-B cell collaboration. Ann N Y Acad Sci 2013;1283:57-66
69. Hinson SR, McKeon A, Fryer JP, et al. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol 2009;66(9):1164-7
70. Ayzenberg I, Kleiter I, Schroder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013; 70(3):394-7
71. Kieseier BC, Stuve O, Dehmel T, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 2013; 70(3):390-3
72. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40(7):1830-5
73. Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 2014;82(15):1302-6
74. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013;12(6):554-62
75. Waubant E. Spotlight on anti-CD20. Int MS J 2008;15(1):19-25
76. Pollinger B, Krishnamoorthy G, Berer K, et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med 2009; 206(6):1303-16
77. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H) 2 hypothesis of T cell-mediated tissue damage. Nat Med 2007;13(2):139-45
78. Gocke AR, Cravens PD, Ben LH, et al. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol 2007;178(3):1341-8
79. Dmytrijuk A, Robie-Suh K, Cohen MH, et al. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 2008; 13(9):993-1000
80. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004;350(6):552-9
81. Ulzheimer JC, Meuth SG, Bittner S, et al. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies. BioDrugs 2010;24(4): 249-74
82. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002;16(3):183-200
83. Korner H, Lemckert FA, Chaudhri G, et al. Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system. Eur J Immunol 1997;27(8):1973-81
84. Klinkert WE, Kojima K, Lesslauer W, et al. TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview. J Neuroimmunol 1997;72(2):163-8
85. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991;87(3): 949-54
86. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47(6):1531-4
87. Arnason B. Tumour necrosis factor neutralization in MS: a cautionary tale. Int MS J 2011;17(2):63-8
88. Weinshenker BG, Bass B, Karlik S, et al. An open trial of OKT3 in patients with multiple sclerosis. Neurology 1991;41(7): 1047-52
89. Racadot E, Rumbach L, Bataillard M, et al. Treatment of multiple sclerosis with anti-CD4 monoclonal antibody. A preliminary report on B-F5 in 21 patients. J Autoimmun 1993;6(6): 771-86
90. Brok HP, van MM, Blezer E, et al. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol 2002;169(11):6554-63
91. Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008; 7(9):796-804
92. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001;19:225-52
93. Howard LM, Miga AJ, Vanderlugt CL, et al. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest 1999;103(2):281-90
94. Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 2006; 24(3):233-8
95. Viglietta V, Bourcier K, Buckle GJ, et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology 2008; 71(12):917-24
96. Daoussis D, Andonopoulos AP, Liossis SN. Targeting CD40L: a promising therapeutic approach. Clin Diagn Lab Immunol 2004; 11(4):635-41
97. Dumont FJ. IDEC-131. IDEC/Eisai. Curr Opin Investig Drugs 2002;3(5):725-34
98. Couzin J. Drug discovery. Magnificent obsession. Science 2005;307(5716):1712-15
99. Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000;6(2):114
100. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354(6): 610-21
101. Bowen JD, Petersdorf SH, Richards TL, et al. Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. Clin Pharmacol Ther 1998;64(3):339-46
102. Bedi GS, Brown AD, Delgado SR, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011;17(10):1225-30
103. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65(11): 1443-8
104. Kim SH, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011;68(11):1412-20.